Brooklyn ImmunoTherapeutics Receivables

Brooklyn ImmunoTherapeutics (BTX) currently reports a receivables of $940K as of December 2025. That compares with $67K in the prior-year period — up 1306.8% year over year. Use the charts on this page to explore Brooklyn ImmunoTherapeutics's receivables history and peer comparisons.

Brooklyn ImmunoTherapeutics's receivables increased from $67K to $940K — a 1306.8% year-over-year increase (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Brooklyn ImmunoTherapeutics reported $940K in receivables as of December 2025. That compares with $67K in the prior-year period — up 1306.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $940K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Brooklyn ImmunoTherapeutics, and consider following BTX for alerts when major investors trade the stock.

Brooklyn ImmunoTherapeutics is classified in the Telecommunications sector. On receivables, it currently shows $940K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Telecommunications are usually more informative than comparing BTX with unrelated industries.